ReviewThe Canadian veterinary journal = La revue veterinaire canadienne2025
The most effective systemic treatment in cats with otodectic mange: A critically appraised topic.
Review in The Canadian veterinary journal = La revue veterinaire canadienne, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Otodectic mange is one of the most common ectoparasitic diseases in cats and the most common cause of feline otitis externa. It is particularly prevalent in young cats between 3 and 6 mo of age and is a veterinary concern, especially in catteries, due to its highly contagious nature. Although there is a risk of overdiagnosis if based solely on cerumen, it is not difficult to identify Results: Isoxazolines (sarolaner, fluralaner, or esafoxolaner) or similar molecules such as tigolaner (a bispyrazole) and macrocyclic lactones (selamectin, eprinomectin, or moxidectin) can lead to parasitological cure and improvement of clinical signs associated with otodectic mange in cats, with rare, mainly cutaneous side effects with mild, autoresolving lesions. Conclusion: Similarities in the clinical and parasitological efficacy of these substances highlight the need for comparative studies that could allow identification of the most efficacious product.
Indexed as
Identifiers
40510273PMC12152695What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.